Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Basal insulins with improved kinetic properties can potentially be produced using acylation by fatty acids that enable soluble, high-molecular weight complexes to form post-injection. A series of insulins, acylated at B29 with fatty acids via glutamic acid spacers, were examined to deduce the structural requirements.
Self-association, molecular masses and hexameric conformations of the insulins were studied using size exclusion chromatography monitored by UV or multi-angle light scattering and dynamic light scattering, and circular dichroism spectroscopy (CDS) in environments (changing phenol and zinc concentration) simulating a pharmaceutical formulation and changes following subcutaneous injection.
With depletion of phenol, insulin degludec and another fatty diacid–insulin analogue formed high molecular mass filament-like complexes, which disintegrated with depletion of zinc. CDS showed these analogues adopting stable T3R3 conformation in presence of phenol and zinc, changing to T6 with depletion of phenol. These findings suggest insulin degludec is dihexameric in pharmaceutical formulation becoming multihexameric after injection. The analogues showed weak dimeric association, indicating rapid release of monomers following hexamer disassembly.
Insulins can be engineered that remain soluble but become highly self-associated after injection, slowly releasing monomers; this is critically dependent on the acylation moiety. One such analogue, insulin degludec, has therapeutic potential.
- Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol. 2002;16(3):475–92. CrossRef
- Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DC, Mercola DA. Three-dimensional atomic structure of insulin and its relationship to activity. Diabetes. 1972;21(2 Suppl):492–505.
- Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Sorensen AR, Voigt HO. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988;333:679–82. CrossRef
- Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J, Kurtzhals P. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498–504. CrossRef
- Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614–20. CrossRef
- Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9(5):648–59. CrossRef
- DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev. 2007;23(6):441–54. CrossRef
- Krüger P, Gilge G, Cabuk Y, Wollmer A. Cooperativity and intermediate states in the T R-structual transformation of insulin. Biol Chem Hoppe-Seyler. 1990;371:669–73. CrossRef
- Kaarsholm NC, Ko HC, Dunn MF. Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin, and miniproinsulin. Biochemistry. 1989;28(10):4427–35. CrossRef
- Jonassen I, Havelund S, Ribel U, Plum A, Loftager M, Hoeg-Jensen T, Volund A, Markussen J. Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm Res. 2006;23:49–55. CrossRef
- Jonassen I, Hoeg-Jensen T, Havelund S, Ribel-Madsen U, Tagmose TM, Madsen P. New insulin derivative comprising a naturally occurring insulin with a side chain attached to the alpha-amino or epsilon-amino in the B chain of the parent insulin, useful in composition for treating diabetes. Patent registered by Novo Nordisk A/S and published in the Derwent World Patents Index (DWPI). Patent no. WO2005012347-A2.
- Jorgensen KH. LarsenUD. Homogeneous mono-125I-insulins. Preparation and characterization of Mono-125I-(Tyr A14)- and Mono-125I-(Tyr A19)-insulin. Diabetologia. 1980;19:546–54. CrossRef
- Kruger P, Gilge G, Cabuk Y, Wollmer A. Cooperativity and intermediate states in the T;R-structural transformation of insulin. Biol Chem Hoppe Seyler. 1990;371:669–73. CrossRef
- Olsen HB, Kaarsholm NC. Structural effects of protein lipidation as revealed by Lys(B29)-myristoyl, des(B30) insulin. Biochemistry. 2000;39:11893–900. CrossRef
- Andrews P. Estimation of molecular size and molecular weights of biological compounds by gel filtration. Methods Biochem Anal. 1970;18:1–53. CrossRef
- Kurtzhals P, Ribel U. Action profile of cobalt(III)-insulin. A novel principle of protraction of potential use for basal insulin delivery. Diabetes. 1995;44(12):1381–5. CrossRef
- Perlmann GE, Longsworth LG. The specific refractive increment of some purified protein. J Am Chem Soc. 1948;70:2719–24. CrossRef
- Wen J, Arakawa T, Philo JS. Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions. Anal Biochem. 1996;240:155–66. CrossRef
- Theisen A, Johann C, Deacon MP, Harding SE. Refractive increment data-book. Nottingham: Nottingham University Press; 2000.
- Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J. 1995;312:725–31.
- Burchard W, Schmidt M, Stockmeyer WH. Information on polydispersity and branching from combined quasi-elastic and integrated scattering. Macromolecules. 1980;13:1265. CrossRef
- Choi WE, Brader ML, Aguilar V, Kaarsholm NC, Dunn MF. The allosteric transition of the insulin hexamer is modulated by homotropic and heterotropic interactions. Biochemistry. 1993;32(43):11638–45. CrossRef
- Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9(3):290–9. CrossRef
- Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold Longer Half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes. 2011;60 Suppl 1:LB11.
- den Engelsmann J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res. 2011;28:920–33. CrossRef
- Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself. 2010;1(4):314–22.
- Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501–7. CrossRef
- Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34(3):661–5. CrossRef
- Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011;377(9769):924–31. CrossRef
- Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34(3):669–74. CrossRef
- Kurtzhals P. How to achieve a predictable basal insulin? Diabetes Metab. 2005;31(4 Pt 2):4S25–33. CrossRef
- Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK, Haahr H. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia. 2010;53(Suppl1):S387.
- Kurzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H, Jonassen I. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes. 2011;60 Suppl 1:LB12.
- Nosek L, Heise T, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect. Diabetes. 2011;60 Suppl 1:LB14.
- Simon AC, Devries JH. The future of basal insulin supplementation. Diabetes Technol Ther. 2011;13 Suppl 1:S103–8.
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 29, Issue 8 , pp 2104-2114
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- acylated insulin
- basal insulin
- insulin analogue
- insulin degludec
- insulin hexamer
- Industry Sectors